Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Dehydromethyltestosterone
2. Dianabol
3. Metanabol
4. Metandienone
5. Methandienone
6. Nerobol
1. Metandienone
2. Methandienone
3. 72-63-9
4. Dianabol
5. Nerobol
6. Metanabol
7. Metandienonum
8. Methandrolone
9. Metandienon
10. Metandrostenolon
11. Metandrostenolone
12. Metastenol
13. Nerobolettes
14. Protobolin
15. Anabolin
16. Andoredan
17. Danabol
18. Dianabole
19. Encephan
20. Naposim
21. Perbolin
22. Stenolon
23. Stenolone
24. Abirol
25. Crein
26. Dehydromethyltestosterone
27. Geabol
28. Anabolicum Medivet
29. Methylandrostenolone
30. 1-dehydromethyltestosterone
31. Compound 17309
32. Nsc-42722
33. Ciba 17309-ba
34. 1,2-dehydro-17-methyltestosterone
35. 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one
36. 1-dehydro-17alpha-methyltestosterone
37. 17alpha-methyl-1-dehydrotestosterone
38. Testosterone, 1-dehydro-17-methyl-
39. 1-dehydro-17-alpha-methyltestosterone
40. 17-alpha-methyl-1-dehydrotestosterone
41. Metandienone [inn]
42. Coz1r7eocc
43. Sterolon
44. 17-beta-hydroxy-17-alpha-methylandrostra-1,4-dien-3-one
45. 1-dehydro-17-methyltestosterone
46. Androsta-1,4-dien-3-one, 17-beta-hydroxy-17-alpha-methyl-
47. 17-beta-hydroxy-17-methyl-androsta-1,4-dien-3-one
48. Metandienone (inn)
49. (17beta)-17-hydroxy-17-methylandrosta-1,4-dien-3-one
50. (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one
51. Ncgc00159415-02
52. Ncgc00159415-04
53. Methandienonum
54. 1-dehydro-17-.alpha.-methyltestosterone
55. Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17b)-
56. Dsstox_cid_3276
57. Methandrostenolonum
58. Dsstox_rid_76952
59. Dsstox_gsid_23276
60. .delta.'-17-methyltestosterone
61. Metandienonum [latin]
62. Metandienona
63. Metandienona [spanish]
64. A1-dehydromethyltesterone
65. Methandrostenolone [usp]
66. Metandrostenolone [dcit]
67. Metandienonum [inn-latin]
68. 1-dehydro-17.alpha.-methyltestosterone
69. 17.alpha.-methyl-1-dehydrotestosterone
70. Cas-72-63-9
71. Ma (van)
72. Ciba 17309 Ba
73. Metandienona [inn-spanish]
74. .delta.1-17.alpha.-methyltestosterone
75. Delta'-17-methyltestosterone
76. Androsta-1, 17.beta.-hydroxy-17-methyl-
77. Tmv 17
78. Hsdb 3360
79. Androsta-1, 17.beta.-hydroxy-17.alpha.-methyl-
80. Unii-coz1r7eocc
81. Delta(1)-17alpha-methyltestosterone
82. Delta-1,17-alpha-methyltestosterone
83. Einecs 200-787-2
84. Nsc 42722
85. Androsta-1, 17-hydroxy-17-methyl-, (17.beta.)-
86. 17-.beta.-hydroxy-17-methyl-androsta-1,4-dien-3-one
87. 17-.beta.-hydroxy-17-.alpha.-methylandrostra-1,4-dien-3-one
88. Delta(sup 1)-17-alpha-methyltestosterone
89. Androsta-1,4-diene-3-one, 17-hydroxy-17-methyl-, (17.beta.)-
90. Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17beta)-
91. 17alpha-methyl-17beta-hydroxyandrosta-1,4-dien-3-one
92. Androsta-1,4-dien-3-one, 17beta-hydroxy-17-methyl-
93. 17-alpha-methyl-17-beta-hydroxy-1,4-androstadien-3-one
94. 17-hydroxy-17-methylandrosta-1,4-dien-3-one
95. Alpha-methyltestosterone
96. Dianabol (tn)
97. Metandienone [who-dd]
98. Methandienone [mart.]
99. Schembl140928
100. Methandrostenolone [mi]
101. Chebi:6810
102. Chembl1418176
103. Dtxsid2023276
104. Methandrostenolone [hsdb]
105. Methandrostenolone [vandf]
106. 1-dehydro-17-methyl-testosterone
107. Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17-beta)-
108. Androsta-1,4-diene-3-one, 17-hydroxy-17-methyl-, (17beta)-
109. Bcp10774
110. Nsc42722
111. Nsc51180
112. Zinc3875469
113. Tox21_111647
114. 1, 2-dehydro-17-methyltestosterone
115. Bbl029917
116. Lmst02020013
117. Nsc-51180
118. S4796
119. Stk801870
120. Akos005267170
121. Tox21_111647_1
122. Ccg-267474
123. Db13586
124. 17-.alpha.-methyl-1-dehydrotestosterone
125. Ncgc00159415-03
126. Ncgc00159415-05
127. 17alpha-methyl-androsta-1,4-dien-3-one
128. Laquo Deltaraquo '-17-methyltestosterone
129. Vs-09501
130. .delta.-1,17-.alpha.-methyltestosterone
131. 17-alpha-methylandrostra-1,4-dien-3-one
132. Laquo Deltaraquo 1-17alpha-methyltestosterone
133. Methandrostenolone 100 Microg/ml In Methanol
134. D00389
135. Ab01332687-02
136. Methandrostenolone 100 Microg/ml In Acetonitrile
137. 17-hydroxy-17-methylandrosta-1,4-dien-3-one #
138. Q417194
139. 17beta-hydroxy-17-methyl-androsta-1,4-dien-3-one
140. Laquo Deltaraquo (sup1)-17alpha-methyltestosterone
141. Androsta-1,4-dien-3-one, 17alpha-methyltestosterone
142. 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, 98%
143. 17beta-hydroxy-17alpha-methyl-androsta-1,4-dien-3-one
144. 17beta-hydroxy-17alpha-methylandrosta-1,4-dien-3-one
145. 17-hydroxy-17-methyl-(17beta)-androsta-1,4-dien-3-one
146. 17-hydroxy-17-methyl-(17beta)-androsta-1,4-diene-3-one
147. Androsta-1,4-dien-3-one, 17.alpha.-hydroxy-17-methyl-
148. 17.beta.-hydroxy-17-methylandrosta-1,4-dien-3-one
149. 17-hydroxy-17-methylandrosta-1,4-dien-3-one (acd/name 4.0)
150. Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17.alpha.)-
151. 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, >=99.0% (hplc)
152. 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, Analytical Standard
153. (1s,3as,3br,9ar,9bs,11as)-1-hydroxy-1,9a,11a-trimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
154. (8r,10r,13s,17s)-17-hydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one
155. (9s,10r,13s,14s,17s)-17-hydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
156. Methandienone Solution, 1.0 Mg/ml In 1,2-dimethoxyethane, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 300.4 g/mol |
|---|---|
| Molecular Formula | C20H28O2 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 300.208930132 g/mol |
| Monoisotopic Mass | 300.208930132 g/mol |
| Topological Polar Surface Area | 37.3 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 589 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anabolic Steroids
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
A two compartment, double-blind, randomized, parallel study was performed comparing methandrostenolone with placebo in the treatment of osteoporosis. The duration of the study was 24 mo. Dependent parameters included total body calcium (TBCa), measured by neutron activation analysis: bone mineral content of the radius (BMC), measured by photon absorptiometry; and total body potassium (TBK), measured by total body counting. A significant increase in TBK occurred in the treated group, primarily in the first 6 mo; thereafter the TBK remained fairly constant. No significant changes in bone mass occurred, except the 6 mo TBCa measurement increased by 11 grams for the methandrostenolone group and decreased by 6 grams for the placebo group (p = .05). Other evidence also suggests that anabolic steroids may not produce sustained uncoupling of bone formation and bone resorption in osteoporosis. If methandrostenolone is capable of producing an increment in bone mass in osteoporosis, it was not readily observable with the sensitivity of the techniques employed in this study
PMID:7026971 Aloia JF et al; Metabolism 30 (11): 1076-9 (1981)
VET: orally, to increase nitrogen retention and increase serum protein values aiding in tissue repair and decrease healing time after surgery, burns, or skin grafts. Also in geriatric states, debilitation, and after chronic infections. As aid in calcium retention in senile, corticosteroid induced, or idiopathic osteoporosis.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 346
Use of anabolic steroids by athletes is not recommended. Objective evidence is conflicting and inconclusive as to whether these medications significantly increase athletic performance by increasing muscle strength. Weight gains reported by athletes are due in part to fluid retention, which is a potentially hazardous side effect of anabolic steroid therapy. The risk of other unwanted effects, such as testicular atrophy and suppression of spermatogenesis in males; menstrual disturbances and virilization, such as deepening of voice, development of acne, and unnatural growth of body hair in females; peliosis hepatis or other hepatotoxicity; and hepatic cancer outweigh any possible benefit received from anabolic steroids and make their use in athletes inappropriate. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 140
Hepatocellular carcinoma has been associated rarely with long-term, high-dose anabolic steroid therapy. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141
Hepatic neoplasms have been associated rarely with long-term, high-dose anabolic steroid therapy. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141
FDA Pregnancy Category X. /CONTRAINDICATED IN PREGNANCY. Studies in animals and or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or risk which clearly outweighs any possible benefit to the patient./
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141
For more Drug Warnings (Complete) data for METHANDROSTENOLONE (19 total), please visit the HSDB record page.
Anabolic Agents
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)
A - Alimentary tract and metabolism
A14 - Anabolic agents for systemic use
A14A - Anabolic steroids
A14AA - Androstan derivatives
A14AA03 - Metandienone
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AE - Androgens for topical use
D11AE01 - Metandienone
It is not known whether anabolic steroids are distributed into breast milk. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141
After oral administration of nerobol, only small amount of its metabolites could be detected in urine of control or patients with hepatic diseases. Half-life of nerobol was greater in patients with cirrhosis than in controls.
PMID:532662 Bodrogi L et al; Acta Pharm Hung 49(5): 194 (1979)
The phase I and phase II metabolism of the anabolic steroid methandrostenolone was investigated following oral administration to a standardbred gelding. In the phase I study, metabolites were isolated from the urine by solid-phase extraction, deconjugated by acid catalysed methanolysis and converted to their O-methyloxime trimethylsilyl derivatives. GC-MS analysis indicated the major metabolic processes to be sequential reduction of the A-ring and hydroxylation at C6 and C16. In the phase II study, unconjugated, beta-glucuronidated and sulfated metabolites were fractionated and deconjugated using a combination of liquid-liquid extraction, enzyme hydrolysis, solid-phase extraction and acid catalysed methanolysis. Derivatization followed by GC-MS analysis revealed extensive conjugation to both glucuronic and sulfuric acids, with only a small proportion of metabolites occurring in unconjugated form.
PMID:11817312 McKinney AR et al; J Chromatogr B Biomed Sci Appl 765 (1): 71-9 (2001)
After oral administration of methandrostenolone to rats small amounts excreted in urine but no metabolites. Larger amounts excreted in feces and 2 components identified as 17alpha-methyl-5beta-androstane-3alpha,17beta-diol and 17alpha-methyl-5alpha-androstane-3beta,17beta-diol.
Steel JW, Schlunegger UP; Can J Pharm Sci 14(2): 50 (1979)
Monolayer cultures of bovine hepatocytes were used to investigate the biotransformation of methandienone in vitro. After incubation of bovine hepatocytes with methandienone, samples were taken at different times. The samples were treated with deconjugation enzymes and extracted with diethyl ether. The metabolites formed were converted to their trimethylsilylether derivatives. By using gas chromatography-mass spectrometry with electron impact and chemical ionisation, several metabolites were identified. After 24 h of incubation with bovine hepatocytes, 83% of the parent compound was converted to its metabolites. The major metabolite found was 6-beta-hydroxymethandienone with a yield of 24%. This compound was identified after comparison with an authentic sample of 6 beta-hydroxymethandienone, which was synthesized chemically.
PMID:10435315 Hooijerink D et al; Analyst 123 (12): 2637-41(1998)
The expression of the cytochrome P450IIIA4 gene in the Saccharomyces cerevisiae yeast using the shuttle vector pYeDP1-8/2 has been carried out. The microsomal fraction isolated from the transformed yeast cells was used for biotransformation of the anabolic steroid hormone-methandrostenolone. The microsomal oxidation products were analyzed by HPLC and two-dimensional TLC. It was shown that microsomes of the yeasts expressing human cytochrome P450IIIA4 catalyze the methandrostenolone conversion into its 6 beta-hydroxy derivative. An identical product is formed via a reaction catalyzed by human liver microsomes. The use of the heterological system of cytochrome P450IIIA4 expression has made it possible to establish its role in methandrostenolone metabolism. The experimental system simulates the first phase of the drug biotransformation in liver cells.
PMID:8155788 Krynetskii Elu et al; Biokhimiia 59 (2): 282-7 (1994)
For more Metabolism/Metabolites (Complete) data for METHANDROSTENOLONE (6 total), please visit the HSDB record page.
Anabolic steroids reverses catabolic processes and negative nitrogen balance by promoting protein anabolism and stimulating appetite if there is concurrently a proper intake of calories and proteins. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141
...Methandrostenolone, was shown to influence cardiac growth in immature male rats by affecting protein synthesis and degradation. The nature of cardiac responses to androgen appear to depend on the prevailing experimental conditions. Protein synthesis was inhibited in the castrate rat and was stimulated by subsequent treatment with androgen. Under conditions of induced overgrowth of the ventricles, androgens gave rise to an attenuation of the effects of aortic constriction on ventricular mass and blood pressure involving smaller changes in protein synthesis and proteolysis. Concentrations of testosterone receptors in ventricular cytosol further indicated that the myocardium is more sensitive to androgen action during the prepubertal phase of the life-span. Changes in amount and properties of the receptors showed them to be functional and responsive to castration, aortic constriction, and administration of the androgens. The androgens affected cardiac protein balance by stimulating the incorporation of radiolabelled amino acid into protein in vivo. They also appeared to influence proteolytic processes involving lysosomal hydrolase activities, but their actions were either stimulatory or inhibitory depending on the internal environment. The heart is a target organ for several hormones including androgen, and our findings fortify the notion that hormone action needs to be investigated alone and in association with other endocrines.
PMID:1804515 Kinson GA et al; Can J Physiol Pharmacol 69 (11): 1698-704 (1991)
The effects of treating groups of rats with four different anabolic androgenic steroids (AAS) (testosterone, nandrolone, methandrostenolone, and oxymetholone) on 5-hydroxytryptamine (5-HT) and dopamine (DA) neurones in different brain regions were examined. The AAS was injected six times with 1 week's interval and the rats were sacrificed 2 days after the final injection. 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured. The effect on DA and 5-HT synthesis rate was analysed as the accumulation of 3,4-dihydroxyphenyl-alanine (DOPA) and 5-hydroxytryptophan (5-HTP), respectively, after inhibition of the amino acid decarboxylase with NSD-1015 (3-hydroxy-benzylhydrazine dihydrochloride). Additionally, the monoamine oxidase (MAO) activity was analysed in the hypothalamus. The DOPAC+HVA/DA ratio was increased in the striatum in all treatment groups. However, the synthesis rate of DA was significantly increased only in the methandrostenolone treated group. The 5-HIAA/5-HT ratio was increased in all treatment groups in the hippocampus, in the frontal cortex in the methandrostenolone-treated animals and in the hypothalamus in the testosterone- and oxymetholone-treated rats, while the 5-HT synthesis rate was not affected by the AAS-treatments. The MAO-A activity was increased in the oxymetholone-treated rats while the other treatment groups were unaffected. The MAO-B activity was not changed. The results indicate that relatively high doses of AAS increase dopaminergic and 5-hydroxytryptaminergic metabolism in male rat brain, probably due to enhanced turnover in these monaminergic systems.
PMID:10217522 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1565900 Thiblin I et al; British Journal of Pharmacology 126: 1301-1306 (1999)
Long-term treatment of female rats with the anabolic steroid hormone Methandrostenolone results in a conspicuous increase of intermediate sized, nonmyofibrillar filaments in muscle cells of the left cardiac ventricle, as revealed by electron microscopy. These filaments, measuring 70 - 110 A in diameter, form a characteristic network at the Z-level of the sarcomere, either encircling or penetrating the Z-bands, and appear to insert into the nuclear membrane. The T-system is accompanied by the filaments adjacent to the site of the couplings. Here they are attached to subsarcolemmal electron-dense patches, which may be Z-line precursor material. The filaments may function as a cytoskeleton, to provide passive support in the mechanism of contraction and to mediate nucleo-sarcolemmal and nucleo-myofibrillar exchange.
PMID:872198 Behrendt H; Cell Tissue Res 180 (3): 303-15 (1977)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
